{"prompt": "['Connect-Home: Testing the Efficacy of Transitional Care of Patients', 'and Caregivers during Transitions from Skilled Nursing Facilities to', 'Home', 'NCT number NCT03810534', 'Document Date 07/13/2020']['Connect-Home: Testing the Efficacy of Transitional Care of Patients and Caregivers during Transitions', 'Version 2.0', 'from Skilled Nursing Facilities to Home', 'Protocol', '13 July 2020', 'Connect-Home: Testing the Efficacy of Transitional Care', 'of Patients and Caregivers during Transitions from', 'Skilled Nursing Facilities to Home', 'Principal Investigator: Mark Toles', 'Funded by: National Institute of Nursing Research', 'Version 2.0', '13 July 2020', 'Summary of Changes from Previous Version:', 'Affected', 'Summary of Revisions Made', 'Rationale', 'Section(s)', 'Section 2, 5, 6, 8', 'Recruitment procedures updated to allot', 'COVID-19 safety precautions', '10', 'for virtual recruitment', 'Table of Contents', 'Statement of Compliance', '3', '1 Protocol Summary', '4', '1.1 Synopsis', '4', '1.2 Schedule of Activities (SoA)', '7', '2 Introduction', '10', '2.1 Study Rationale', '10', '2.2 Background', '10', '2.3 Risk/Benefit Assessment', '11', '2.3.1 Known Potential Risks', '11', '2.3.2 Known Potential Benefits', '13', '2.3.3 Assessment of Potential Risks and Benefits', '14', '3 STUDY OBJECTIVES', '15', '4 Study Design', '19', '4.1 Overall Design', '19', '4.2 Scientific Rationale for Study Design', '20', '4.3 End of Study Definition', '20', '5 Study Population', '21', '5.1 Inclusion Criteria', '21', '5.2 Exclusion Criteria', '21', '5.3 Screen Failures', '22', '5.4 Strategies for Recruitment and Retention', '22', '6 Study Intervention', '24', '6.1 Study Intervention(s) Administration', '24', 'Connect-Home Protocol v2.0 13Jul2020', '1']['Connect-Home: Testing the Efficacy of Transitional Care of Patients and Caregivers during Transitions', 'Version 2.0', 'from Skilled Nursing Facilities to Home', 'Protocol', '13 July 2020', '6.1.1 Study Intervention Description', '24', '6.2 Measures to Minimize Bias: Randomization and Blinding', '27', '6.3 Study Intervention Compliance', '27', '7 Study Intervention Discontinuation and Participant Discontinuation/Withdrawal', '29', '7.1 Discontinuation of Study Intervention', '29', '7.2 Participant Discontinuation/Withdrawal from the Study', '29', '7.3 Lost to Follow-Up', '30', '8 STUDY ASSESSMENTS AND PROCEDURES', '31', '8.1 Efficacy Assessments', '31', '8.2 Adverse Events and Serious Adverse Events', '35', '8.2.1 Definition of Adverse Events (AE)', '35', '8.2.2 Definition of Serious Adverse Events (SAE)', '35', '8.2.3 Classification of an Adverse Event', '35', '8.2.4 Time Period and Frequency for Event Assessment and Follow-Up', '36', '8.2.5 Adverse Event Reporting', '36', '8.2.6 Serious Adverse Event Reporting', '36', '8.3 Unanticipated Problems', '37', '8.3.1 Definition of Unanticipated Problems (UP)', '37', '8.3.2 Unanticipated Problem Reporting', '37', '9 Statistical Considerations', '38', '9.1 Statistical Hypotheses', '38', '9.2 Sample Size Determination', '38', '9.3 Populations for Analyses', '39', '9.4 Statistical Analyses', '39', '9.4.1 General Approach', '39', '9.4.2 Analysis of the Primary Efficacy Endpoint(s)', '40', '9.4.3 Analysis of the Secondary Endpoint(s)', '40', '9.4.4 Baseline Descriptive Statistics', '41', '10 Supporting Documentation and Operational Considerations', '43', '10.1 Regulatory, Ethical, and Study Oversight Considerations', '43', '10.1.1 Informed Consent Process', '43', '10.1.2 Study Discontinuation and Closure', '43', '10.1.3 Confidentiality and Privacy', '44', '10.1.4 Future Use of Stored Specimens and Data', '44', '10.1.5 Safety Oversight', '44', '10.1.6 Clinical Monitoring', '45', '10.1.7 Quality Assurance and Quality Control', '45', '10.1.8 Data Handling and Record Keeping', '45', '10.1.9 Protocol Deviations', '45', '10.1.10 Publication and Data Sharing Policy', '46', '10.1.11 Conflict of Interest Policy', '46', '10.2 Abbreviations', '47', '10.3 Protocol Amendment History', '48', '11 References', '49', 'Connect-Home Protocol v2.0 13Jul2020', '2']\n\n###\n\n", "completion": "END"}